Develops drugs for metabolic diseases and hunger-associated conditions.
Dec 2025Revenue $0.00/yrExpenses $62.7M/yr
No trendCash runway ≈ 1.1 years from Jun 2026
Figures by year
When will Aardvark Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $0.00 and expenses $62.7M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $62.7M | −$62.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.